A Phase 3 interventional study of DBV712 250 mcg and Placebo in Allergy and Peanut Allergy, sponsored by DBV Technologies. Active, not recruiting at 91 sites in 8 countries. Open to participants aged 1 Year to 3 Years. Per ClinicalTrials.gov, last updated 2026-07-22.
Sponsored by DBV Technologies · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing palforzia in Peanut Hypersensitivity — none open to participants now, 3 under way, 2 of them phase 3. Palforzia · Peanut Hypersensitivity.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, this one is the 3rd largest by planned enrollment, is the only one that started in 2025, is one of 4 in phase 3, and was the 10th registered.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
Browse Peanut Hypersensitivity studies →None of the 10 studies testing palforzia in Peanut Hypersensitivity is open now. The open studies under Peanut Hypersensitivity, anywhere →
Palforzia: first FDA approval 2020 (Palforzia). What it is approved for, and how studies give it, is on its page →
Of the 18 Peanut Hypersensitivity studies recruiting now, 2 (11%) set no upper age limit and 16 (89%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 1 Year to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
This study's planned enrollment of 480 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Median enrollment 105 across the 10 interventional studies. Of the 7 that completed or were terminated, 5 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 10 have an industry lead sponsor. The 6 most frequent:
DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
13 studies in Peanut Hypersensitivity by DBV Technologies: none open now, 2 under way, 2 of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 13 studies in Peanut Hypersensitivity by DBV Technologies, this one is the 3rd largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2025, is one of 7 in phase 3, and was the 13th registered.
DBV Technologies’s Peanut Hypersensitivity studies by the year they started, since 2010.
1 of the studies testing palforzia in Peanut Hypersensitivity that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07003919Phase 3DBV TechnologiesSafety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers) | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies testing palforzia in Peanut Hypersensitivity, from their registry updates:
Among DBV Technologies’s 13 in Peanut Hypersensitivity:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to assess the 6-month safety of DBV712 250 micrograms (mcg) in subjects 1 through 3 years of age with peanut allergy.
This is a Phase 3 randomized double-blind, placebo-controlled (DBPC) study of 6-months duration to assess the safety of DBV712 250 mcg in subjects 1 through 3 years of age with peanut allergy. Participants who complete the 6-month DBPC period will be eligible to enter an optional 18-month open-label extension (OLE).
The overall maximum study duration for each participant will be approximately 112 weeks: Screening Period of 6-weeks, DBPC Treatment Period of 26-weeks, Open-label Period of 78-weeks and Follow-up Period of 2-weeks.
For participation eligibility, please refer to eligibility criteria section.
Randomization of eligible participants will occur in a 3:1 ratio to DBV712 250 mcg (active treatment) or placebo, respectively.
166 studies on the registry are indexed under Peanut Hypersensitivity; 27 are open to participants now.
This study's planned enrollment of 480 is above the median of 50 across 127 interventional studies indexed under Peanut Hypersensitivity.
Browse Peanut Hypersensitivity studies →DBV Technologies is the lead sponsor of 16 studies on the registry; 1 is open to participants now.
Compared within Peanut Hypersensitivity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypersensitivity. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 6 months.
Combination Product: DBV712 250 mcg
Participants will apply DBV712 matching placebo epicutaneous system (or patch), daily for a period of 6 months.
Combination Product: Placebo
The 6-month DBPC period will be followed by an optional open-label extension (OLE) period during which eligible participants will receive DBV712 250 mcg for a duration of 18 months (representing 24 months of active treatment for those participants initially randomized to DBV712 250 mcg and 18 months of active treatment for those participants that were initially randomized to placebo).
Combination Product: DBV712 250 mcg
DBV712 250 mcg epicutaneous system.
Also known as: Viaskin® Peanut Patch
DBV712 matching placebo epicutaneous system.
DBPC Treatment Period: Adverse Events (AEs), Treatment-Emergent Adverse Events (TEAEs), and Serious Adverse Events (SAEs)
Time frame: Through DBPC Treatment Period, 6 months
Concentration of peanut-specific IgE (kUA/L) at baseline and month 6.
Time frame: Month 6
Concentration of peanut-specific IgG4 (mg/L) at baseline and month 6.
Time frame: Month 6
DBPC Treatment Period: Change from baseline in peanut Skin Prick Test (SPT) mean wheal diameters
Time frame: Month 6
Started Jun 2025 (actual). Primary completion is estimated for Nov 2026, 17 months after the start.
Of 15 phase 3 interventional studies under Peanut Hypersensitivity, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 42. This study's planned 17 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Palforzia
DBV Technologies